Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

• Status: Terminated
• Trial end date: 2018-01-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Females of non-childbearing potential and/or male subjects

• Clinical diagnosis of Parkinson's disease.

• Parkinson's Disease Hoehn & Yahr Stage I-III inclusive

• Treatment naïve or history of prior incidental treatment with dopaminergic agents for no more than 28 days

• Able to refrain from any Parkinson's disease medication not permitted by the protocol.

Exclusion Criteria:

• History or presence of atypical Parkinsonian syndrome.

• Severe acute or chronic medical or psychiatric condition or cognitive impairment or laboratory abnormality.

• Any condition possibly affecting drug absorption.

• Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.